B cell-directed therapies in type 1 diabetes
B cells play a pathogenic role as antigen-presenting cells and autoantibody secretors in the lead up to T cell-mediated autoimmune destruction of insulin-producing beta cells in type 1 diabetes (T1D). This has led to significant interest in the use of B cell depletion therapies as a treatment for T1D. In this review, we compare results from five recent studies that used distinct B cell-depleting agents and protocols to successfully prevent and even reverse T1D in the non-obese diabetic (NOD) mouse model. We discuss how information gained from animal studies could be used to improve on the positive outcomes of a completed phase II clinical trial of the B cell-depleting drug rituximab in humans with recent-onset T1D.
|Authors||Marino, E.; Silveira, P.A.; Stolp, J.; Grey, S. T.:|
|Responsible Garvan Author||(missing name)|
|Publisher Name||TRENDS IN IMMUNOLOGY|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21531625|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/11000|